Dyno Therapeutics Unveils AI-Engineered AAV Capsid Dyno-bn8 for Muscle Gene Therapy

WATERTOWN, Mass. — November 11, 2025 — Dyno Therapeutics, Inc., a genetic technologies company leveraging artificial intelligence (AI) to optimize gene delivery, today announced the launch of Dyno-bn8, a novel adeno-associated virus (AAV) gene delivery vector. Unveiled at the company’s Genetic Agency Technology Conference (GATC), Dyno-bn8 is engineered to precisely target skeletal and cardiac muscle with best-in-class potential.

Breakthrough NHP Results: Low Dose and Enhanced Safety

Data from non-human primate (NHP) studies demonstrate that Dyno-bn8 overcomes the major limitations of current AAV vectors—namely, the need for high doses and high off-target liver accumulation.

Key findings of the NHP study include:

• Exceptional Low-Dose Efficacy: Dyno-bn8 achieved therapeutic delivery via systemic intravenous (IV) injection at a dose of 5.2e12 vg/kg. This represents a 25-fold reduction compared to typical muscle gene therapies dosed at 1.33e14 vg/kg.
• Muscle Tropism: The capsid transduced 81% of skeletal muscle cells and 20% of cardiac cells throughout the body, outperforming competitor capsids like MyoAAV-4E in head-to-head comparisons.
• Improved Safety Profile: Dyno-bn8 features substantial liver detargeting, which is critical for reducing liver toxicity and immunological responses often associated with high-dose AAV administration.

Dyno-bn8 was created by training AI sequence design models on proprietary NHP performance data, confirming the role of AI in solving complex in vivo delivery problems.

Furthermore, Dyno reported that Dyno-bn8 is ready for the clinic. The new capsid is compatible with existing AAV9-based processes. The company also confirmed that the capsid interacts with both human and NHP muscle receptors, underscoring its human translatability.